The role of thalidomide in myeloma patients eligible for high-dose therapy

被引：0
|
作者：
Cavo, M. [1 ]
机构：
[1] Univ Bologna, Sch Med, Seragnoli Inst Hematol & Med Oncol, Bologna, Italy
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2007年 / 92卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
下载
收藏
页码：28 / 29
页数：2
相关论文
共 50 条
  • [1] The role of bortezomib in myeloma patients eligible for high-dose therapy
    Jagannath, S.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 (06): : 29 - 30
  • [2] The role of lenalidomide in myeloma patients eligible for high dose therapy
    Rajkumar, S. V.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 (06): : 30 - 31
  • [3] THE ROLE OF THALIDOMIDE MAINTENANCE FOLLOWING HIGH DOSE THERAPY IN PATIENTS WITH MULTIPLE MYELOMA
    Bila, J.
    Lekovic, D.
    Smiljanic, M.
    Sretenovic, A.
    Vujic, D.
    Veljkovic, D.
    Antic, D.
    Sefer, D.
    Kraguljac, N.
    Andjelic, B.
    Todorovic, M.
    Elezovic, I.
    Tomin, D.
    Gotic, M.
    Mihaljevic, B.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 391 - 392
  • [4] Impact of low-dose thalidomide as maintenance therapy in advanced multiple myeloma patients following high-dose therapy
    Andreini, A.
    Ruggeri, G.
    Sorio, M.
    Tecchio, C.
    Frattini, F.
    Ledro, S.
    Perbellini, C.
    de Sabata, D.
    Quaresmini, G.
    Benedetti, F.
    BONE MARROW TRANSPLANTATION, 2010, 45 : S149 - S149
  • [5] Impact of low-dose thalidomide as maintenance therapy in advanced multiple myeloma patients following high-dose therapy
    Andreini, A.
    Randon, F.
    Tecchio, C.
    Quaresmini, G.
    Frattini, F.
    Di Bella, R.
    Sorio, M.
    Ledro, S.
    Perbellini, C.
    de Sabata, D.
    Benedetti, F.
    BONE MARROW TRANSPLANTATION, 2009, 43 : S152 - S152
  • [6] Management of patients with multiple myeloma: Emphasizing the role of high-dose therapy
    Kyle, RA
    CLINICAL LYMPHOMA, 2001, 2 (01): : 21 - 28
  • [7] High-dose therapy for myeloma
    Barlogle, B
    LEUKEMIA & LYMPHOMA, 1998, 30 : 9 - 11
  • [8] Low efficacy of thalidomide in improving response after induction in myeloma patients candidate to high-dose therapy.
    Corso, Alessandro
    Mangiacavalli, Silvia
    Barbarano, Luciana
    Zappasodi, Patrizia
    Banfi, Luciano
    Montalbetti, Luigi
    Mazzone, Antonio
    Fava, Sergio
    Frigerio, Guido
    Isa, Luciano
    Montanara, Sergio
    Perego, Daniele
    Savare, Maria
    Uziel, Lij
    Vismara, Alessandro
    Campiotti, Leonardo
    Fiumano, Mario
    Lazzarino, Mario
    Morra, Enrica
    BLOOD, 2006, 108 (11) : 1019A - 1019A
  • [9] Unique role of cytogenetics in the prognosis of patients with myeloma receiving high-dose therapy and autotransplants
    Tricot, G
    Sawyer, JR
    Jagannath, S
    Desikan, KR
    Siegel, D
    Naucke, S
    Mattox, S
    Bracy, D
    Munshi, N
    Barlogie, B
    JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (07) : 2659 - 2666
  • [10] Thalidomide maintenance following high-dose therapy in multiple myeloma: a UK myeloma forum phase 2 study
    Feyler, Sylvia
    Rawstron, Andy
    Jackson, Graham
    Snowden, John A.
    Cocks, Kim
    Johnson, Roderick J.
    BRITISH JOURNAL OF HAEMATOLOGY, 2007, 139 (03) : 429 - 433
12345